Abstract
Ceftazidime-avibactam (CAZ-AVI) is a novel cephalosporin beta lactamase inhibitor combination that has shown activity against carbapenem-resistant Enterobactericeae. Data are limited on its utilization in the treatment of carbapenem-resistant Klebsiella pneumoniae osteomyelitis in solid organ transplant patients. We describe a case report on the use of CAZ-AVI in the treatment of vertebral osteomyelitis in a renal transplant recipient.
Keywords:
CRKP; osteomyelitis; renal transplant.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
MeSH terms
-
Amikacin / therapeutic use
-
Anti-Bacterial Agents / therapeutic use*
-
Azabicyclo Compounds / therapeutic use*
-
Ceftazidime / therapeutic use*
-
Drug Combinations
-
Drug Resistance, Bacterial*
-
Female
-
Humans
-
Kidney Transplantation
-
Klebsiella Infections / drug therapy
-
Klebsiella Infections / microbiology*
-
Klebsiella pneumoniae / drug effects
-
Middle Aged
-
Osteomyelitis / drug therapy
-
Osteomyelitis / microbiology*
-
Postoperative Complications / drug therapy
-
Postoperative Complications / microbiology
-
Spine
-
Transplant Recipients
Substances
-
Anti-Bacterial Agents
-
Azabicyclo Compounds
-
Drug Combinations
-
avibactam, ceftazidime drug combination
-
Amikacin
-
Ceftazidime